understanding us fda regulatory responsibilities for cell therapy companies
Published 2 years ago • 525 plays • Length 59:19Download video MP4
Download video MP3
Similar videos
-
43:14
introduction to regulatory science at the fda
-
36:56
fda’s clinical regulatory perspective: designing first-in-human trial for cellular and gene therapy
-
1:21
what does fda regulate?
-
46:52
preclinical considerations for cell and gene therapy products, an fda perspective
-
17:45
understanding the fda approval process for gene therapies: step-by-step explanation
-
1:56:15
understanding fda inspections and data
-
29:42
cmc considerations for car t cell product development
-
57:11
unmet needs in regulatory science for generic drugs
-
1:10:23
fda clinical investigator training course (citc) 2022, day 1 – part 3
-
7:42:41
fda regulatory education for industry (redi) annual conference 2023 – plenary drugs day 1
-
1:43:09
fda nanoday symposium 2022 welcome, keynote and session 1
-
21:20
investigator responsibilities - safety reporting for investigational drugs and devices
-
1:57:53
public meeting: using methods from pfdd guidance 1 and guidance 2 meeting #2
-
1:05:51
wscs16 -day 2 - fda oversight in regenerative medicine
-
1:00:16
right-to-try or right-to-ask? understanding right-to-try and fda’s expanded access
-
10:39
consulting companies and fda limitations panel discussion
-
48:20
overcoming manufacturing challenges for gene-enabled cell therapies
-
2:09:08
fda clinical investigator training course (citc) 2022, day 2 – part 1
-
2:12:15
examining concerns regarding fda's proposed changes to generic drug labeling